123938-86-3

MIC: 4 μg/mL ( E. coli ), 32 μg/mL ( S. aureus ) and <0.5 μg/mL ( S. enteritidis )

Glycol chitosan derivatives have been successfully applied to deliver antimicrobial agents and anticancer drugs such as chemodrugs, genes, and photosensitizers (PSs), either by physical encapsulation or chemical conjugation. Glycol chitosan can be directly linked with hydrophobic drugs to generate amphiphilic compounds that can also form nanoparticles (NPs) for cell imaging and drug delivery. The use of Glycol chitosan derivatives for cell imaging and drug delivery has several advantages, including superb tumor-homing ability in the case of Glycol chitosan NPs based on enhanced permeability and retention (EPR) effect, low cytotoxicity, ease of chemical modification, great biocompatibility, and biodegradability.
The hydrophobic modification of Glycol chitosan is already confirmed, such as Glycol chitosan bearing a 5β-cholanic acid moiety and deoxycholic acid-Glycol chitosan, could self-assemble into nanoparticles, acting as a promising vehicle for hydrophobic drugs and genes.